-+ 0.00%
-+ 0.00%
-+ 0.00%
3 British Biotech Stocks To Own In November 2026
Share
Listen to the news

AI linked goods are now a major driver of global trade growth, and that surge in demand for new therapies, data tools and diagnostics is pulling specialist research into the spotlight. For United Kingdom biotech stocks with solid balance sheets, this creates a rare window where science and commerce intersect. This article picks out three of the stronger candidates from the screener that merit a closer look.

The three biotech stocks discussed below are only a sample of what screened well, and the full results surfaced 4 more United Kingdom companies with equally compelling narratives that are not covered in this article. If you want to identify and analyze a broader set of biotech ideas with similar balance sheet strength, head straight into the Biotech Stocks screener.

AstraZeneca (LSE:AZN)

AstraZeneca is one of the largest biopharma players in the Biotech Stocks screener, with a heavy focus on complex biologic and targeted therapies across cancer, rare diseases and immune conditions that fits the theme, and the analyst consensus Narrative on Simply Wall St captures why that matters.

"The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular or metabolic therapies, is now underpinned by management's disclosure of 12 programs each with risk adjusted peak sales potential above US$5b and several more in the US$3b to US$5b range. This could support high margin revenue growth and earnings as these assets progress from development to launch."

What really changes the story for AstraZeneca is how one unseen pressure on future pricing power and cost discipline ultimately filters through to earnings quality.

That pricing pressure and cost control tug of war is exactly what the full narrative for AstraZeneca unpacks, revealing how AstraZeneca’s earnings story could be quietly accelerating.

LSE:AZN Earnings & Revenue Growth as at Nov 2026
LSE:AZN Earnings & Revenue Growth as at Nov 2026

Hikma Pharmaceuticals (LSE:HIK)

Hikma Pharmaceuticals plugs into the biotech theme through its oncology and specialty injectable drugs used in hospital settings. The analyst consensus Narrative on Simply Wall St argues the real story is how that higher complexity mix could reshape the whole earnings profile.

"Hikma Pharmaceuticals is materially increasing R&D investment and concentrating it through three global platforms with disciplined NPV and IRR stage gates. This aims to shift the portfolio toward fewer, higher value complex products that can support higher net margins and earnings quality over time."

What those higher value therapies eventually do to pricing power and competitive intensity could be the quiet swing factor for Hikma Pharmaceuticals.

Hikma Pharmaceuticals develops and sells generic, specialty and branded medicines across injectables, respiratory and oral products. Injectables generate about US$1.4b, Hikma Rx US$1.0b and Branded US$0.9b, with the group valued at roughly £3.4b by the market.

That quiet swing factor is exactly what the full narrative for Hikma Pharmaceuticals unpacks, highlighting where Hikma Pharmaceuticals may be quietly accelerating and where the risk or reward balance could be misread.

LSE:HIK Earnings & Revenue Growth as at Nov 2026
LSE:HIK Earnings & Revenue Growth as at Nov 2026

Genus (LSE:GNS)

Genus brings the Biotech Stocks theme into the barnyard by using applied genetics and reproductive technology to sell dairy and bull semen, embryos and breeding pork lines worldwide, with about £356 million from PIC and £300 million from ABS, and a market value near £1.47 billion.

The analyst consensus Narrative on Simply Wall St describes Genus as a genetics driven breeder where royalty economics and applied biotech give the animal health theme significant leverage.

"The build out of Genus’ high margin, recurring PIC royalty model, including more than 50% royalty revenue growth in China on top of 6% group royalty growth in H1 FY26, points to further expansion of royalty driven revenue and operating profit as contracts mature and penetrate a larger share of global pig herds."

The key question now is how a shift in future earnings mix might reshape what investors are willing to pay for those genetics cash flows.

That earnings mix question is exactly what the full narrative for Genus lays out, separating durable genetics cash flows from risks that might be masking Genus’ potential re rating.

LSE:GNS Earnings & Revenue Growth as at Nov 2026
LSE:GNS Earnings & Revenue Growth as at Nov 2026

Seeking Alternatives Before The Crowd?

Fresh ideas move first. Breakout themes, quiet momentum and under the radar stories often get caught once prices are already flying. Scan these while it matters and consider acting before more attention arrives.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending